EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort

Vibeke Strande iD, Charlotte Lund, Milada Hagen, May-Bente Bengtson, Raziye Boyar Cetinkaya, Trond Espen Detlie iD, Svein Oskar Frigstad, Ole Høie, Asle W Medhus, Magne Henriksen, Kristina I Aass Holten, Øistein Hovde und 11 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Vibeke Strande und 22 weiteren Autor:innen. Beteiligte Einrichtung: Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Colectomy, Disease Progression, Biological Products. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stiftelsen Dam, Ferring Pharmaceuticals, South-Eastern Health Authorities in Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The introduction of biologic therapies and the ‘treat‐to‐target’ treatment strategy may have changed the disease course of ulcerative colitis (UC).

Aims

To describe the early disease course and disease outcome at 1‐year follow‐up in a population‐based inception cohort of adult patients with newly diagnosed UC.

Methods

The Inflammatory Bowel Disease in South‐Eastern Norway (IBSEN) III study is a population‐based inception cohort study with prospective follow‐up. Patients newly diagnosed with inflammatory bowel disease during 2017–2019 were included. Patients ≥18 years at diagnosis of UC who attended the 1‐year follow‐up were investigated. We registered clinical, endoscopic and demographic data at diagnosis and 1‐year follow‐up.

Results

We included 877 patients with UC (median age 36 years (range: 18–84), 45.8% female). At diagnosis, 39.2% presented with proctitis, 24.7% left‐sided colitis and 36.0% extensive colitis. At the 1‐year follow‐up, 13.9% experienced disease progression, and 14.5% had received one or more biologic therapies. The colectomy rate was 0.9%. Steroid‐free clinical remission was observed in 76.6%, and steroid‐free endoscopic remission in 68.7%. Anaemia and initiation of systemic steroid treatment at diagnosis were associated with biologic therapy within the first year after diagnosis.

Conclusion

In this population‐based inception cohort, colectomy rate in the first year after diagnosis was low, and a high proportion of patients were in remission at 1‐year follow‐up. The use of biologic therapy increases, consistent with findings from previous studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeColectomyDisease ProgressionBiological ProductsHumansFemaleAdultMaleMiddle AgedAgedYoung AdultAdolescentNorwayProspective StudiesAged, 80 and overFollow-Up StudiesTreatment OutcomeCohort StudiesRemission Induction

Substanzen

Biological Products

Autor:innen und Institutionen

  • Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Public Health, Oslo Metropolitan University, Oslo, Norway.
  • Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
  • Department of Gastroenterology, Vestfold Hospital Trust, Tønsberg, Norway.
  • Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.

ORCID-Profile: Vibeke Strande, Trond Espen Detlie

Förderung

  • Stiftelsen Dam
  • Ferring Pharmaceuticals
  • South-Eastern Health Authorities in Norway
  • Takeda Pharmaceutical Company
  • Tillotts Pharma
  • Pfizer
  • Ferring

Zitieren

APA

Strande, V., Lund, C., Hagen, M., Bengtson, M. B., Cetinkaya, R. B., Detlie, T. E., Frigstad, S. O., Høie, O., Medhus, A. W., Henriksen, M., Aass Holten, K. I., Hovde, Ø., Huppertz-Hauss, G., Johansen, I., Olsen, B. C., Opheim, R., Ricanek, P., Torp, R., Tønnessen, T., …, & Kristensen, V. A. (2024). Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18097

Vancouver

Strande V, Lund C, Hagen M, Bengtson MB, Cetinkaya RB, Detlie TE, et al. Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18097

BibTeX
@article{Strande2024,
  author = {Strande, Vibeke and Lund, Charlotte and Hagen, Milada and Bengtson, May-Bente and Cetinkaya, Raziye Boyar and Detlie, Trond Espen and Frigstad, Svein Oskar and Høie, Ole and Medhus, Asle W and Henriksen, Magne and Aass Holten, Kristina I and Hovde, Øistein and Huppertz-Hauss, Gert and Johansen, Ingunn and Olsen, Bjørn Christian and Opheim, Randi and Ricanek, Petr and Torp, Roald and Tønnessen, Tor and Vatn, Simen and Aabrekk, Tone Bergene and Høivik, Marte Lie and Kristensen, Vendel A},
  title = {Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18097}
}
Kostenlos starten →